:: صفحه اصلي :: درباره نشريه :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
:: ::
برگشت به فهرست مقالات برگشت به فهرست نسخه ها
BCG vaccine and pulmonary tuberculosis
چکیده:   (341 مشاهده)

Tuberculosis (TB) is one of the most important public health problems in the world and has been declared as a global emergency by the World Health Organization (WHO) in 1993. Bacillus Calmette-Guérin (BCG) is one of the first developed vaccines to prevent TB. Unfortunately, BCG vaccine has had a limited duration of protection and has shown controversial and variable levels of efficacy, especially against pulmonary TB. On the other hand, efforts in production of new forms of this vaccine have been in vain and revaccination is not considered as a suitable strategy to control the disease. Considering that TB affects adults mostly between the ages of 15 and 59, pulmonary TB is more common than disseminated TB and BCG vaccine has had a minimal effect on the global burden of pulmonary TB. Before introducing a new, safe and effective vaccine, combined strategies in the field of control and treatment of TB rather than vaccination are necessary.

متن کامل [PDF 365 kb]   (117 دریافت)    
نوع مطالعه: Review article |
دریافت: ۱۳۹۶/۳/۳۰ | پذیرش: ۱۳۹۶/۳/۳۰ | انتشار: ۱۳۹۶/۳/۳۰
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

کد امنیتی را در کادر بنویسید >



XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tafreshi S. BCG vaccine and pulmonary tuberculosis. vacres. 2016; 3 (8 and 9) :36-40
URL: http://vacres.pasteur.ac.ir/article-1-98-fa.html
BCG vaccine and pulmonary tuberculosis. تحقیقات واکسن. 1395; 3 (8 و 9) :36-40

URL: http://vacres.pasteur.ac.ir/article-1-98-fa.html

برگشت به فهرست مقالات برگشت به فهرست نسخه ها
تحقیقات واکسن Vaccine Research
Persian site map - English site map - Created in 0.187 seconds with 826 queries by yektaweb 3470